REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:34 UTC
-
New hope for tough lymphoma: targeted drug combo shows promise in early trial
Disease control OngoingThis phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 12:54 UTC
-
New combo tackles tough lymphomas
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC